Published in:
Open Access
01-07-2012 | Original article
Combination chemotherapy with S-1 plus cisplatin for gastric cancer that recurs after adjuvant chemotherapy with S-1: multi-institutional retrospective analysis
Authors:
Kohei Shitara, Satoshi Morita, Kazumasa Fujitani, Shigenori Kadowaki, Nobuhiro Takiguchi, Naoki Hirabayashi, Masazumi Takahashi, Masakazu Takagi, Yukihiko Tokunaga, Ryoji Fukushima, Yasuhiro Munakata, Kazuhiro Nishikawa, Akinori Takagane, Takaho Tanaka, Yoshiaki Sekishita, Junichi Sakamoto, Akira Tsuburaya
Published in:
Gastric Cancer
|
Issue 3/2012
Login to get access
Abstract
Background
It is unclear whether S-1 plus cisplatin is effective for patients with recurrent gastric cancer after adjuvant S-1 chemotherapy.
Methods
We retrospectively evaluated the efficacy of S-1 plus cisplatin in patients whose gastric cancer recurred after adjuvant S-1 chemotherapy.
Results
In the 52 patients evaluated, the median duration of adjuvant S-1 chemotherapy was 8.1 months, and the median recurrence-free interval (RFI) since the last administration of adjuvant S-1 was 6.4 months. Among the 36 patients with measurable lesions, 7 achieved a complete or partial response, and 13 were evaluated as having stable disease, for an overall response rate of 19.4% and a disease control rate of 55.6%. For all patients, the median progression-free survival (PFS) was 4.8 months, and the median overall survival (OS) was 12.2 months. Compared with patients with an RFI of <6 months (n = 25), patients with an RFI of ≥6 months (n = 27) had a significantly higher response rate (5.0 vs. 37.5%, respectively), longer PFS (2.3 vs. 6.2 months, respectively), and longer overall survival (7.3 vs. 16.6 months, respectively). According to a multivariate Cox model including performance status (PS) and reason for discontinuation of adjuvant S-1, an RFI of 6 months was still significantly associated with PFS and OS.
Conclusions
S-1 plus cisplatin is effective for patients with gastric cancer that recurs after adjuvant S-1 chemotherapy, especially for those with an RFI of ≥6 months.